It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Neurofilament light chain (NfL) has been demonstrated to correlate with multiple sclerosis disease severity as well as treatment response. Nevertheless, additional serum biomarkers are still needed to better differentiate disease activity from disease progression. The aim of our study was to assess serum glial fibrillary acid protein (s-GFAP) and neurofilament light chain (s-NfL) in a cohort of 129 multiple sclerosis (MS) patients. Eighteen primary progressive multiple sclerosis (PPMS) and 111 relapsing remitting MS (RRMS) were included. We showed that these 2 biomarkers were significantly correlated with each other (R = 0.72, p < 0.001). Moreover, both biomarkers were higher in PPMS than in RRMS even if multivariate analysis only confirmed this difference for s-GFAP (130.3 ± 72.8 pg/ml vs 83.4 ± 41.1 pg/ml, p = 0.008). Finally, s-GFAP was correlated with white matter lesion load and inversely correlated with WM and GM volume. Our results seem to confirm the added value of s-GFAP in the context of multiple sclerosis.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Univ Montpellier, INSERM, Département de Neurologie, CRC sclérose en Plaques, CHU Montpellier, Montpellier, France (GRID:grid.121334.6) (ISNI:0000 0001 2097 0141)
2 Montpellier University Hospital Center, Department of Neuroradiology, Montpellier, France (GRID:grid.157868.5) (ISNI:0000 0000 9961 060X); CHRU de Montpellier, I2FH, Institut D’Imagerie Fonctionnelle Humaine, Hôpital Gui de Chauliac, Montpellier, France (GRID:grid.157868.5) (ISNI:0000 0000 9961 060X); Université de Montpellier, Laboratoire Charles Coulomb, CNRS UMR 5221, Montpellier, France (GRID:grid.121334.6) (ISNI:0000 0001 2097 0141)
3 Centre Hospitalier Regional Universitaire de Montpellier, Economic Evaluation Unit, Montpellier, France (GRID:grid.157868.5) (ISNI:0000 0000 9961 060X)
4 Centre Hospitalier Regional Universitaire de Montpellier, Laboratoire de Biochimie-Protéomique Clinique, Montpellier, France (GRID:grid.157868.5) (ISNI:0000 0000 9961 060X); IRB, Institute of Regenerative Medicine and Biotherapy IRMB – INSERM, Montpellier, France (GRID:grid.157868.5)
5 Siemens Healthcare, Advanced Clinical Imaging Technology, Lausanne, Switzerland (GRID:grid.121334.6); University of Lausanne, Department of Radiology, Lausanne University Hospital, Lausanne, Switzerland (GRID:grid.9851.5) (ISNI:0000 0001 2165 4204); École Polytechnique, LTS5, Lausanne, Switzerland (GRID:grid.9851.5)
6 Siemens Healthcare, Advanced Clinical Imaging Technology, Lausanne, Switzerland (GRID:grid.9851.5); University of Lausanne, Department of Radiology, Lausanne University Hospital, Lausanne, Switzerland (GRID:grid.9851.5) (ISNI:0000 0001 2165 4204); École Polytechnique, LTS5, Lausanne, Switzerland (GRID:grid.9851.5)